期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 61, 期 4, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02409-16
关键词
cefepime-tazobactam
资金
- Wockhardt Bio AG (Switzerland)
- Achaogen
- Actavis
- Actelion
- Allergan
- American Proficiency Institute (API)
- AmpliPhi
- Anacor
- Astellas
- AstraZeneca
- Basilea
- Bayer
- BD
- Cardeas
- Cellceutix
- CEM-102 Pharmaceuticals
- Cempra
- Cerexa
- Cidara
- Cormedix
- Cubist
- Debiopharm
- Dipexium
- Dong Wha
- Durata
- Enteris
- Exela
- Forest Research Institute
- Furiex
- Genentech
- GSK
- Helperby
- ICPD
- Janssen
- Lannett
- Longitude
- Medpace
- Meiji Seika Kasha
- Melinta
- Merck
- Motif
- Nabriva
- Novartis
- Paratek
- Pfizer
- Pocared
- PTC Therapeutics
- Rempex
- Roche
- Salvat
- Scynexis
- Seachaid
- Shionogi
- Tetraphase
- Medicines Co.,
- Theravance
- ThermoFisher
- VenatoRX
- Vertex
- Zavante
Cefepime-tazobactam (WCK 4282) is currently under clinical development for use at a dosage of 2 g/2 g every 8 h. A total of 7,981 isolates were collected from 146 medical centers (39 countries) in 2014 as a part of the SENTRY Antimicrobial Surveillance Program, and their susceptibilities to cefepime-tazobactam (with tazobactam at fixed concentrations of 4 and 8 mu g/ml) were tested by a reference broth microdilution method. Isolates were mainly from patients with pneumonia (29.5%) and bloodstream infections (26.9%). Cefepime-tazobactam (with tazobactam at a fixed concentration of 8 mu g/ml) and cefepime inhibited 96.9 and 87.9% of Enterobacteriaceae strains at <= 8 mu g/ml. The activity of cefepime-tazobactam against Enterobacteriaceae strains was comparable to that of meropenem (96.7% of isolates were susceptible) and greater than that of piperacillin-tazobactam (87.7% susceptible). All Enterobacteriaceae species from the United States except Klebsiella pneumoniae had > 99.0% of isolates inhibited by cefepime-tazobactam at <= 8/8 mu g/ml. The prevalence of the extended-spectrum beta-lactamase (ESBL)-screening-positive phenotype was the highest among Escherichia coli isolates in China (66.3%) and among K. pneumoniae isolates (58.0%) in Latin America. Cefepime-tazobactam at <= 8/8 mu g/ml inhibited 98.7 and 71.3% of ESBL-screening-positive phenotype E. coli strains and K. pneumoniae strains, respectively. Meropenem showed limited activity against ESBL-screening-positive phenotype K. pneumoniae strains (69.6% susceptible). Cefepime-tazobactam was active against Enterobacter spp. (MIC50 and MIC90, 0.06 and 0.5 mu g/ml, respectively), including ceftazidime-nonsusceptible isolates (96.1% of isolates were inhibited by cefepimetazobactam at <= 8/8 mu g/cl). The activity of cefepime-tazobactam against Pseudomonas aeruginosa (82.4 and 91.6% of isolates were inhibited by cefepime-tazobactam at <= 8/8 and <= 16/8 mu g/ml, respectively) was comparable to that of meropenem and piperacillin- tazobactam (79.2% susceptible). In summary, cefepime-tazobactam was highly active against P. aeruginosa and Enterobacteriaceae strains, including ESBLscreening-positive phenotype E. coli strains and ceftazidime-nonsusceptible Enterobacter spp. These results support the further clinical development of the cefepimetazobactam combination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据